Oral Immunotherapy Guidance With Symptom-Based Dose Adjustment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral immunotherapy protocols for food allergies lack uniformity, leading to frequent allergic reactions, hospital visits, and high anxiety, necessitating a need for standardized, customizable, and safe treatment at home.
Innovation Solution
A food allergy treatment service provision method using oral immunotherapy, facilitated by a smartphone application and system, that generates personalized guidelines for immunotherapy based on patient information, monitors symptoms, and adjusts protocols according to adverse event grades, allowing home administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If oral immunotherapy is administered without uniform protocols, then treatment flexibility is improved, but treatment safety and effectiveness deteriorate due to frequent allergic reactions
Solution Approach 1:
The system changes parameters such as food antigen dosage, escalation rate, and maintenance amount based on individual patient characteristics (age, weight, allergy severity). The protocol dynamically adjusts these parameters to achieve both safety and effectiveness, resolving the contradiction between flexibility and reliability.
Solution Approach 2:
The system implements continuous feedback mechanisms where patient responses (symptoms, adverse events) are monitored and fed back to adjust the immunotherapy protocol. This feedback loop ensures treatment safety while maintaining flexibility to adapt to individual patient needs.
2Productivity
If rapid escalation of food antigen is used, then treatment effectiveness is improved, but frequency of allergic reactions increases
Solution Approach 1:
The escalation rate is made dynamic rather than fixed, adjusting the speed of food antigen increase based on patient tolerance and response. This allows effective treatment progression while minimizing allergic reactions by adapting the escalation pace to individual patient capabilities.
Solution Approach 2:
The protocol implements precautionary measures before escalation, including pre-medication with antihistamines or steroids, and careful monitoring readiness. This cushioning approach prevents or mitigates allergic reactions while maintaining treatment effectiveness.
3Reliability
If frequent hospital visits are required for oral immunotherapy monitoring, then treatment safety is improved, but patient compliance and psychological comfort deteriorate
Solution Approach 1:
The system enables patients to self-monitor and self-report symptoms and adverse events at home through mobile applications or digital platforms. This self-service approach maintains treatment safety through continuous monitoring while eliminating the need for frequent hospital visits, thereby improving compliance and psychological comfort.
Solution Approach 2:
Digital communication tools and telemedicine platforms serve as intermediaries between patients and healthcare providers, enabling remote monitoring and consultation. This intermediary system maintains safety through professional oversight while reducing the burden of frequent in-person hospital visits.
4Adaptability or versatility
If heterogeneous oral immunotherapy programs are implemented, then treatment adaptability is improved, but standardization and evaluation consistency deteriorate
Solution Approach 1:
The system creates a universal framework that can accommodate different patient types and allergy conditions through standardized protocols. This universal system maintains adaptability to individual needs while ensuring consistency in evaluation criteria, dosage ranges, and safety monitoring across all patients.
Data Source
AI summary
A method for providing a food allergy treatment service using oral immunotherapy, includes: transmitting patient information input into a patient terminal to a medical staff terminal; generating oral immunotherapy guide information on the basis of the patient information; transmitting the oral immunotherapy guide information to the patient terminal and displaying the same; when symptom information about symptoms after protein intake is input to the patient terminal, transmitting the symptom information to the medical staff terminal; analyzing the symptom information to determine an adverse reaction grade; and modifying the oral immunotherapy guide information, transmitting the same to the patient terminal, and displaying the oral immunotherapy guide information.


